Liege

• Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) Ended recruitment
  2023-509671-17-00 5 2017-07-12 Breast Cancer
• Study of Abemaciclib with Pembrolizumab in Patients with Stage IV Lung Cancer or Breast Cancer Ended recruitment
  2023-506788-32-00 2 2016-11-15 Lung Cancer or Breast Cancer
• A Phase Ib-II Study of tazemetostat (EPZ-6438) in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or high risk Follicular Lymphoma (FL … Ended recruitment
  2024-515846-18-00 7 2016-09-19 Newly diagnosed Diffuse Large B Cell Lymphoma
• A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Rheumatoid Arthritis who are on a Stable Dose of Meth … Ended recruitment
  2022-501017-31-00 5 2016-05-10 Rheumatoid arthritis
• CheckMate 274 Ended recruitment
  2022-500630-29-00 5 2016-05-06 Subjects with High Risk Invasive Urothelial Carcinoma
• Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) Ended recruitment
  2023-507889-89-00 5 2016-02-19 Respiratory tract infection
• An Efficacy and Safety Study of JNJ56021927 (ARN509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS Ended recruitment
  2023-505246-26-00 5 2016-01-27 High- or very-high risk, localized or locally advanced prostate cancer
• PALLAS - PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy vers … Ended recruitment
  2024-514841-12-00 5 2015-10-27 To determine whether the addition of palbociclib to adjuvant endocrine
• A Study of abemaciclib Combined with Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Ended recruitment
  2023-506781-30-00 5 2014-09-17 Breast cancer
• Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended recruitment
  2024-511096-15-00 5 2014-08-01 Breast Cancer
• A large-scale comparative study evaluating an intravenous treatment, cabazitaxel, and radiation therapy to the pelvic lymph nodes in patient … Ended recruitment
  2024-517622-25-00 5 2013-12-06 Patients with localized prostate cancer and high-risk features of rela
• Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free … Ended recruitment
  2024-516198-61-00 5 2013-06-05 Patients with high risk of relapse, ER+ and HER2- primary non-metastat
• Chemotherapy or chemotherapy + hormonotherapy in women over 70 with HER2 receptor-negative but estrogen receptor-positive breast cancer acco … Ended recruitment
  2024-516996-34-00 5 2012-04-12 oestrogen-receptor (ER)-positive HER2-negative breast carcinoma
• Mechanisms of Action of Paradoxical Responses to Zolpidem: A Multimodal Study Halted
  2023-507404-31-03 4 2025-02-11 Patients with acquired partial/total vision impairments
• A Phase 3 Study of NTLA 2001 in participants with amyloidosis with cardiac muscle disease. Halted
  2023-507220-23-00 5 2024-07-26 Transthyretin Amyloidosis with Cardiomyopathy
• A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulator … Halted
  2024-512626-28-00 5 2024-03-28 Duchenne Muscular Dystrophy
• A randomized, open-label, multicentric, two-arm pivotal trial of SonoCloud-9 combined with carboplatin (CBDCA) vs standard of care lomustine … Halted
  2023-505829-14-00 5 2023-12-22 First recurrence glioblastoma
• Study to assess the safety and expression of RO7494222 (SRP-9001) in participants under the age of 4 with Duchenne muscular dystrophy Halted
  2023-509901-57-00 4 2023-10-26 Duchenne Muscular Dystrophy
• Ketamine to treat patients with post-comatose disorders of consciousness Halted
  2024-518433-29-00 4 2022-01-01 Disorder of Consciousness, severe brain injury
• A First-in-human study to learn how safe the study drug BAY2965501 is, find the best dose (single drug & combination), how it affects the bo … Ended
  2023-507905-33-00 1 2025-09-30 Advanced solid tumors
• Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents with Sickle Cell Disease during Vaso-Occlusive Crisis Ended
  2024-513440-29-00 10 2025-06-25 Sickle cell disease vaso-occlusive crisis
• A clinical study of MK-6916 in healthy people (MK-6916-006) Ended
  2025-521487-36-00 3 2025-06-02 Acute and chronic Pain
• Safety, Tolerability, and Efficacy of NVG-2089 in Participants with CIDP Ended
  2024-515386-34-00 4 2025-05-29 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• Open label, single-center, cross-over randomized, relative bioavailability study comparing a new pitolisant hydrochloride tablet formulatio … Ended
  2025-520980-41-00 3 2025-04-08 narcolepsy with cataplexy

Showing 481–504 of 639 trials